NHS to Cover Lynparza for Breast and Prostate Cancer

Shortly after a recommendation last year from the UK’s National Institute for Care and Health Excellence (NICE), the NHS agreed to provide Lynparza, Merck and AstraZeneca’s prostate and breast cancer drug, to patients in Wales and England. The move comes after positive results showing the drug lowered mortality in breast cancer patients by a third.

According to Phil Taylor, “At the same time, it has endorsed use of the drug in men with advanced, incurable BRCA-positive prostate cancer who have seen their disease progress despite hormone therapy, in order to slow down progression and extend their lives.”

To read more, click here.

(Source: Pharma Phorum, April 6^th, 2023)